Samsung Medical Center

Combining osimertinib with savolitinib showed a 32% objective response rate in NSCLC patients with EGFR mutations and high MET overexpression/amplification after osimertinib failure, with a 49% response rate among those with high MET expression.

Osimertinib plus savolitinib combo shows high, durable ORR in EGFR-mutant, MET-overexpressed/amplified NSCLC patients progressing on osimertinib, per SAVANNAH trial. Safety profile consistent with known profiles; no new safety signals. Detailed results to be presented and submitted for regulatory review. FDA granted fast track designation in 2023.

Samsung Medical Center (SMC) in South Korea leads healthcare innovation through digital transformation, receiving the 2024 HIMSS Davies Award. SMC integrates digital health technologies like Remote Patient Monitoring (RPM) and AI to enhance operational efficiency and patient care, reducing average hospital stay from 7.3 to 5.3 days. SMC also explores CAR-T cell therapy and aims to make advanced treatments accessible. Ranked third in Oncology and 18th in the World's Best Smart Hospitals, SMC sets a global standard in healthcare innovation.

HUTCHMED announces positive results from SAVANNAH Phase II trial showing TAGRISSO® (osimertinib) plus ORPATHYS® (savolitinib) effective for MET-driven resistance in EGFR-mutated NSCLC, with high ORR and durability.

SAVANNAH Phase II trial shows TAGRISSO® (osimertinib) plus ORPATHYS® (savolitinib) effective for EGFRm NSCLC with MET overexpression/amplification, with high ORR and durability.

Korea faces hurdles integrating innovative medical tech due to regulatory and reimbursement issues, as discussed at the K-Healthcare Business Forum. Medical IP's AI-based imaging solutions, like DeepCatch X, aim to replace traditional tests but face adoption challenges. Guardant Health urges regulatory reform for liquid biopsy access, while Ybrain's neuroengineering innovations struggle with market entry and reimbursement.

EVER-132-002 study, compliant with Helsinki and ICH GCP guidelines, was approved by national authorities and ethics committees. It enrolled HR+HER2- metastatic or locally recurrent BC patients from China, Korea, and Taiwan, requiring prior chemotherapy and measurable disease. Patients were randomized 1:1 to receive SG or chemotherapy, with PFS as the primary endpoint. Secondary endpoints included OS, ORR, DoR, CBR, safety, and QoL. Assessments involved tumor measurements, safety evaluations, and QoL questionnaires. Statistical analysis included sample size calculation, HR estimation, and safety summaries. The study design details are available in the Nature Portfolio Reporting Summary.

A randomized, double-blind, placebo-controlled, non-inferiority trial in 3 Korean hospitals aims to compare ROTEM-guided TXA administration with preemptive TXA in elective cardiovascular surgery, focusing on postoperative blood loss, transfusions, and complications. The trial, registered in 2023, involves 764 patients and follows institutional protocols for perioperative management, with data managed by a CRO.

A research team led by Professor Song Yong-sang developed a diagnostic method to predict chemotherapy resistance in ovarian cancer patients using a tool called the Ovarian Cancer Assay. The method, with 85% accuracy and 100% sensitivity, identifies 31 key genes linked to resistance, focusing on platinum-based chemotherapy. Clinical trials are set to begin, involving multiple institutions and supported by precision medicine companies.